Taysha Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Taysha Gene Therapies
TSHA Stock  USD 1.66  0.02  1.22%   
Taysha Gene financial statements provide useful quarterly and yearly information to potential Taysha Gene Therapies investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Taysha Gene financial statements helps investors assess Taysha Gene's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Taysha Gene's valuation are summarized below:
Gross Profit
8.3 M
Market Capitalization
340.3 M
Enterprise Value Revenue
31.7349
Revenue
8.3 M
Earnings Share
(0.36)
We have found one hundred twenty available fundamental trend indicators for Taysha Gene Therapies, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Taysha Gene Therapies current market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. As of March 25, 2025, Market Cap is expected to decline to about 411.1 M. In addition to that, Enterprise Value is expected to decline to about 295.5 M

Taysha Gene Total Revenue

5.78 Million

Check Taysha Gene financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Taysha Gene's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.3 M, Interest Expense of 96.9 K or Selling General Administrative of 27.4 M, as well as many indicators such as Price To Sales Ratio of 87.02, Dividend Yield of 0.0 or PTB Ratio of 6.35. Taysha financial statements analysis is a perfect complement when working with Taysha Gene Valuation or Volatility modules.
  
Check out the analysis of Taysha Gene Correlation against competitors.

Taysha Gene Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets170.9 M160.4 M69 M
Slightly volatile
Other Current Liabilities13.8 M12.9 M5.7 M
Slightly volatile
Total Current Liabilities33.9 M26.2 M13.8 M
Slightly volatile
Non Current Assets Total24.4 M18.2 M9.8 M
Slightly volatile
Non Currrent Assets Other2.3 M2.4 M1.2 M
Slightly volatile
Common Stock Shares Outstanding158.3 M250.1 M84.7 M
Slightly volatile
Liabilities And Stockholders Equity170.9 M160.4 M69 M
Slightly volatile
Other Current Assets2.9 M3.1 M2.4 M
Slightly volatile
Other Stockholder Equity424 M677.9 M171.6 M
Slightly volatile
Total Liabilities80.3 M88.8 M32.5 M
Slightly volatile
Total Current Assets146.5 M142.1 M59.1 M
Slightly volatile
Other Liabilities3 M4.7 M1.5 M
Slightly volatile
Property Plant And Equipment Net24.9 M15.9 M8.8 M
Slightly volatile
Accounts Payable7.1 M3.6 M4.5 M
Slightly volatile
Cash123.4 M139 M212.9 M
Slightly volatile
Cash And Short Term Investments123.4 M139 M212.9 M
Slightly volatile
Capital Surpluse249.9 M281.2 M306.6 M
Slightly volatile
Property Plant And Equipment Gross26.4 M19.4 M9.3 M
Slightly volatile
Non Current Liabilities Other1.8 M1.3 M1.1 M
Slightly volatile
Property Plant Equipment61.1 M58.2 M17.1 M
Slightly volatile
Short and Long Term Debt Total16.5 M17.4 M57 M
Slightly volatile
Long Term Debt43.9 M43.9 M38.3 M
Slightly volatile
Current Deferred Revenue16.4 M9.8 M30 M
Slightly volatile
Short Term Debt1.7 M1.9 M1.6 M
Slightly volatile
Common Stock1.8 K2.3 K1.2 K
Slightly volatile

Taysha Gene Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.3 M1.2 M3.2 M
Slightly volatile
Selling General Administrative27.4 M29 M11.3 M
Slightly volatile
Selling And Marketing Expenses965.2 K1.6 M741.6 K
Slightly volatile
Other Operating Expenses97.8 M99.8 M40.1 M
Slightly volatile
Research Development69.4 M66 M28.6 M
Slightly volatile
Total Operating Expenses97.8 M99.8 M40.1 M
Slightly volatile
Interest Income7.3 M6.9 M1.1 M
Slightly volatile
Cost Of Revenue1.2 M1.6 M451.5 K
Slightly volatile
Reconciled Depreciation942.7 K1.2 M332.4 K
Slightly volatile

Taysha Gene Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Borrowings32 M36 M39.2 M
Slightly volatile
Depreciation788 K1.2 M322.9 K
Slightly volatile
Other Non Cash Items5.9 M6.2 M10.9 M
Slightly volatile
Capital Expenditures355.3 K374 K4 M
Slightly volatile
Total Cash From Financing Activities118.2 M76.7 M226.5 M
Slightly volatile
End Period Cash Flow143.3 M141.6 M57.9 M
Slightly volatile
Change To Netincome70 M66.6 M21.8 M
Slightly volatile
Sale Purchase Of Stock232.9 M262 M285.6 M
Slightly volatile
Stock Based Compensation13.3 M13.1 M6.7 M
Slightly volatile
Begin Period Cash Flow144.4 M146.5 M60.3 M
Slightly volatile
Cash And Cash Equivalents Changes201 M226.1 M246.5 M
Slightly volatile
Cash Flows Other Operating12 M13.5 M14.7 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio87.0251.93139
Slightly volatile
Stock Based Compensation To Revenue1.491.57246.0827
Slightly volatile
Capex To Depreciation0.290.3004698
Slightly volatile
EV To Sales35.4637.3284126
Slightly volatile
Payables Turnover0.210.20.0585
Slightly volatile
Sales General And Administrative To Revenue3.33.474512.6772
Slightly volatile
Research And Ddevelopement To Revenue7.527.920430.8009
Slightly volatile
Capex To Revenue0.04260.04498.1112
Slightly volatile
Cash Per Share0.530.55582.6442
Slightly volatile
Days Payables Outstanding1.8 K1.8 K57 K
Slightly volatile
Net Debt To EBITDA1.911.38344.3149
Slightly volatile
Current Ratio9.065.41923.7138
Slightly volatile
Debt To Equity0.230.24274.5234
Pretty Stable
Capex Per Share0.00140.00150.1083
Slightly volatile
Revenue Per Share0.03040.03330.0197
Slightly volatile
Interest Debt Per Share0.06630.06980.076
Slightly volatile
Debt To Assets0.10.10830.286
Pretty Stable
Days Of Payables Outstanding1.8 K1.8 K57 K
Slightly volatile
Ebt Per Ebit1.310.97641.3254
Slightly volatile
Long Term Debt To Capitalization0.190.19530.3174
Pretty Stable
Total Debt To Capitalization0.190.19530.4123
Very volatile
Debt Equity Ratio0.230.24274.5234
Pretty Stable
Quick Ratio9.065.41923.7138
Slightly volatile
Net Income Per E B T0.730.920.7863
Slightly volatile
Cash Ratio5.045.301325.3888
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.291.00461.257
Slightly volatile
Fixed Asset Turnover0.370.52520.1817
Slightly volatile
Debt Ratio0.10.10830.286
Pretty Stable
Price Sales Ratio87.0251.93139
Slightly volatile
Asset Turnover0.0430.0520.0276
Slightly volatile
Gross Profit Margin0.00480.00540.0059
Slightly volatile

Taysha Gene Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap411.1 M432.7 M2.6 B
Slightly volatile
Enterprise Value295.5 M311.1 M2.5 B
Slightly volatile

Taysha Fundamental Market Drivers

Cash And Short Term Investments139 M

Taysha Upcoming Events

26th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
26th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Taysha Gene Financial Statements

Taysha Gene stakeholders use historical fundamental indicators, such as Taysha Gene's revenue or net income, to determine how well the company is positioned to perform in the future. Although Taysha Gene investors may analyze each financial statement separately, they are all interrelated. For example, changes in Taysha Gene's assets and liabilities are reflected in the revenues and expenses on Taysha Gene's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Taysha Gene Therapies. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue9.8 M16.4 M
Total Revenue8.3 M5.8 M
Cost Of Revenue1.6 M1.2 M
Stock Based Compensation To Revenue 1.57  1.49 
Sales General And Administrative To Revenue 3.47  3.30 
Research And Ddevelopement To Revenue 7.92  7.52 
Capex To Revenue 0.04  0.04 
Revenue Per Share 0.03  0.03 
Ebit Per Revenue(10.98)(11.52)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
ZLABZai Lab
ASLEAerSale Corp
ATSAT S Austria
When determining whether Taysha Gene Therapies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Taysha Gene's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Taysha Gene Therapies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Taysha Gene Therapies Stock:
How To Invest In Taysha
Details
Is Taysha Stock a good investment?
Details
What is Taysha Gene's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Taysha Gene Correlation against competitors.
You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Taysha Gene. If investors know Taysha will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Taysha Gene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.36)
Revenue Per Share
0.033
Quarterly Revenue Growth
(0.44)
Return On Assets
(0.33)
Return On Equity
(1.22)
The market value of Taysha Gene Therapies is measured differently than its book value, which is the value of Taysha that is recorded on the company's balance sheet. Investors also form their own opinion of Taysha Gene's value that differs from its market value or its book value, called intrinsic value, which is Taysha Gene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Taysha Gene's market value can be influenced by many factors that don't directly affect Taysha Gene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Taysha Gene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Taysha Gene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Taysha Gene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY